Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in Relapsed/Recurrent Adult T-cell Leukemia-lymphoma
NCT01724177Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2012
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in adult T-cell leukemia-lymphoma (ATLL), sponsored by Celgene Corporation. Started Nov 2012; status: completed.
02
Drugs
lenalidomide
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NCT01724177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01724177.